The risks of concurrent treatment with tenofovir and aminoglycosides in patients with HIV-associated tuberculosis

Southern African Journal of HIV Medicine

Volumn , Issue 39, 2011, Pages 43-45

  Kenyon, Chris ^a,b   Wearne, Nicci ^b   Burton, Rosie ^a,b   Meintjes, Graeme ^a,b,c  

^a GF Jooste Hospital   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EFAVIRENZ; KANAMYCIN; LAMIVUDINE; STAVUDINE; STREPTOMYCIN; TENOFOVIR;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; CONFUSION; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; WEAKNESS;

EID: 79957980923     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v12i1.214     Document Type: Article

References (20)

1. Clinical Guidelines for the Management of HIV & AIDS in Adults and Adolescents. Pretoria: National Department of Health, Republic of South Africa, 2010.
2. Galloe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995;48(1):39-43.
3. Sandavol RM, Molitoris BA. Gentamicin traffics through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am J Physiol Renal Physiol 2004;286(4):617-624.
4. Hobbie SN, Akshay S, Kalapala SK, Bruell CM, Scherbakov D, Bottger EC. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 2008;105(52):20888-20893.
5. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689-696.
6. Côté HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006;11(1):79-86.
7. Gitman MD, Hirschwerk D, Baskin CH, Singhai PC. Tenofovir-induced kidney injury. Expert Opin Drug Saf 2007;6(2):155-164. (Pubitemid 46380809)
8. Schooley RT, Ruane P, Myers RA, et al.; Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16(9):1257-1263.
9. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292(2):191-201.
10. Gallant JE, DeJesus E, Arribas JR, et al.; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354(3):251-260.
11. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40(8):1194-1198. (Pubitemid 40490248)
12. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006;7(2):105-111.
13. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42(2):283-290. (Pubitemid 43054205)
14. Mocroft A, Kirk O, Reiss P, et al. EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24(11):1667-1678.
15. Cooper RD, Wiebe N, Smith N, Keiser P, Naiker S, Tonelli M. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51(5):496-505.
16. Reid A, Stohr W, Walker S, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008;46:1271-1281. (Pubitemid 351589914)
17. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273-1281. (Pubitemid 46883481)
18. Castellano C, Williams W, Kepler T, et al. Clinical predictors of tenofovir-associated nephrotoxicity in HIV-1 infected patients. Presented at the 17th International AIDS Conference, Mexico City, 3-8 August 2008. Abstract WEAB0104.
19. Viread (Tablets) Package Insert, 23 February 2007.
20. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23:437-446.